My London Pharmacy wegovy cost typically ranges from £199 to £299 per month for private prescriptions, depending on the dosage strength and treatment phase. Wegovy (semaglutide 2.4 mg) is a prescription-only weight management medication licensed by the MHRA for adults with obesity or overweight with weight-related complications. Whilst NHS provision costs just £9.90 per prescription in England, access is highly restricted to specialist weight management services with strict eligibility criteria. Private pharmacies offer broader access but at considerably higher cost. This article examines Wegovy pricing at My London Pharmacy, compares NHS versus private costs, and explains how to access treatment safely through regulated providers.

Wegovy Pricing at My London Pharmacy

Wegovy (semaglutide 2.4 mg) is a prescription-only weight management medication available through private pharmacies across the UK, including My London Pharmacy. The cost of Wegovy varies depending on the dosage strength and treatment duration, with prices typically reflecting the medication's position as a premium weight-loss therapy.

At My London Pharmacy, patients can expect to pay between £199 and £299 per month for Wegovy (as of early 2024), depending on the specific dose prescribed during the titration schedule. The treatment begins with a lower dose (0.25 mg weekly) and gradually increases over 16–20 weeks to the maintenance dose of 2.4 mg weekly, as outlined in the UK product licence. Initial starter packs are generally priced at the lower end of the range, whilst maintenance doses command higher monthly costs. These prices usually include the pre-filled injection pen but may not cover the initial consultation fee, which can range from £40 to £150 depending on whether the assessment is conducted online or face-to-face.

It is important to note that Wegovy pricing can fluctuate based on supply chain factors and pharmacy pricing policies. My London Pharmacy, like other private providers, sets its own pricing structure within the competitive private healthcare market. Patients should confirm current prices directly with the pharmacy, as promotional offers or package deals may occasionally be available. Additionally, the total cost of treatment should factor in ongoing monitoring appointments, blood tests if required, and the long-term nature of weight management therapy, which NICE guidance (TA875) recommends for a maximum of 2 years within specialist weight management services.

NHS vs Private Wegovy Prescriptions: Cost Comparison

The cost difference between NHS and private Wegovy prescriptions is substantial and represents a significant consideration for patients seeking this treatment. On the NHS, Wegovy is available at the standard prescription charge of £9.90 per item in England (prescriptions are free in Scotland, Wales, and Northern Ireland), though charges may vary in specialist or hospital settings. However, NHS access to Wegovy is highly restricted and subject to strict eligibility criteria established by NICE guidance (TA875).

To qualify for NHS-funded Wegovy, patients must have a body mass index (BMI) of 35 kg/m² or above (or 32.5 kg/m² for people from South Asian, Chinese, other Asian, Middle Eastern, Black African, or African-Caribbean family backgrounds) plus at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea. Additionally, patients must be treated within a specialist weight management service. These stringent criteria mean that most individuals seeking Wegovy will not qualify for NHS provision, with waiting times for specialist services varying considerably across different regions.

In contrast, private prescriptions through pharmacies like My London Pharmacy offer considerably broader access, though at significantly higher cost—typically £200–£300 monthly compared to the NHS prescription charge. Private providers generally follow the marketing authorisation criteria, requiring a BMI of 30 kg/m² or above (or 27 kg/m² with weight-related complications) and can initiate treatment following a remote or in-person consultation, often within days rather than months. For patients who meet NHS criteria, the cost saving could be substantial—potentially thousands of pounds annually—making NHS provision vastly more economical where accessible. However, for those outside NHS eligibility or unable to access specialist services, private treatment remains the only viable option despite the considerable financial commitment required.

How to Access Wegovy Through My London Pharmacy

Accessing Wegovy through My London Pharmacy follows a structured clinical pathway designed to ensure patient safety and treatment appropriateness. The process typically begins with an online or in-person consultation with a registered prescriber—either a GP, pharmacist prescriber, or specialist clinician affiliated with the pharmacy. During this assessment, the clinician will review your medical history, current medications, weight management goals, and eligibility for treatment based on BMI and comorbidity criteria.

Prospective patients should prepare for the consultation by gathering relevant information including current weight and height measurements, details of previous weight loss attempts, any existing medical conditions (particularly cardiovascular disease, thyroid disorders, or history of pancreatitis), and a complete list of current medications. The prescriber will assess your medical history, including any thyroid disease which requires careful consideration before starting treatment. Blood pressure measurement and consideration of baseline blood tests (including HbA1c, lipid profile, and thyroid function) may be recommended based on your individual clinical needs, though requirements vary between providers.

Once approved, the prescription is issued and the medication can be collected from My London Pharmacy or delivered to your home, depending on the service options available. The pharmacy will provide comprehensive instructions on injection technique, pen storage (refrigeration required for unopened pens at 2-8°C; after first use can be stored for 28 days below 30°C or in a refrigerator), and the dose escalation schedule. Follow-up arrangements are essential and typically include monthly check-ins to monitor weight loss progress, assess tolerability, and adjust treatment as needed. Patients should expect to commit to regular monitoring throughout treatment, with consideration given to discontinuing treatment if less than 5% body weight is lost after six months at the maintenance dose, as recommended in the UK product information. It is advisable to contact My London Pharmacy directly via their website or telephone to confirm current service availability, pricing, and appointment options before beginning the process.

What Is Wegovy and How Does It Work?

Wegovy is the brand name for semaglutide 2.4 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed for chronic weight management in adults with obesity or overweight with weight-related complications, and in adolescents aged 12 years and above with body weight above 60kg. Originally developed for type 2 diabetes treatment (marketed as Ozempic at lower doses), semaglutide was approved by the MHRA for weight management in 2022 following robust clinical trial evidence demonstrating significant and sustained weight loss.

The mechanism of action of Wegovy operates through multiple physiological pathways that collectively reduce body weight. Semaglutide is a synthetic analogue of human GLP-1, a naturally occurring incretin hormone released by the intestine in response to food intake. By binding to GLP-1 receptors in the brain—particularly in appetite-regulating centres of the hypothalamus—Wegovy reduces hunger and increases feelings of fullness (satiety). Additionally, it slows gastric emptying, meaning food remains in the stomach longer, prolonging the sensation of fullness after meals. These combined effects lead to reduced caloric intake without requiring conscious calorie restriction, though lifestyle modifications including dietary improvements and increased physical activity remain essential components of effective weight management.

Wegovy is administered as a once-weekly subcutaneous injection using a pre-filled pen device, typically injected into the abdomen, thigh, or upper arm. The treatment follows a carefully designed dose escalation schedule starting at 0.25 mg weekly and increasing every four weeks through 0.5 mg, 1 mg, and 1.7 mg before reaching the maintenance dose of 2.4 mg weekly. This gradual titration minimises gastrointestinal side effects, which are the most common adverse reactions.

Common side effects include nausea (reported by up to 44% of patients in clinical trials), diarrhoea, vomiting, constipation, and abdominal pain. These effects are usually mild to moderate, occur predominantly during dose escalation, and typically diminish over time. More serious but rare adverse effects include pancreatitis, gallbladder disease (including gallstones), and hypoglycaemia (particularly in patients taking other glucose-lowering medications). There is also a risk of dehydration and acute kidney injury, especially with severe gastrointestinal side effects, and patients with type 2 diabetes should be monitored for diabetic retinopathy complications. Wegovy may increase heart rate and should not be used during pregnancy or breastfeeding, with effective contraception recommended during treatment and for at least two months after discontinuation. Wegovy should not be used in combination with other GLP-1 receptor agonists.

Patients should seek immediate medical attention if they experience severe abdominal pain, persistent vomiting, or signs of pancreatitis. Any suspected side effects should be reported through the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk). Clinical trials demonstrated that Wegovy produces an average weight loss of 12–15% of initial body weight over 68 weeks when combined with lifestyle intervention, significantly exceeding results achieved with lifestyle changes alone. However, treatment is intended for long-term use, as weight regain commonly occurs following discontinuation.

Frequently Asked Questions